Apollo Therapeutics, working closely with Prof. Randall Johnson and his team in the Department of Physiology, Development & Neuroscience at the University of Cambridge have developed a small molecule that promotes memory T cell populations – octyl S-2-hydroxyglutarate – and have demonstrated applicability to human CAR-T systems.
Licensing opportunity: octyl S-2-hydroxyglutarate
- Promotes memory T cell populations, conferring persistence and proliferation that translates into enhanced anti-tumour efficacy
- Characterised in mouse and human systems
- Fully compatible with human CAR-T lentiviral transduction protocols
- Opportunity for clinical differentiation
Make an Enquiry